Coherus Oncology (CHRS) Return on Capital Employed Growth (3y) (2017 - 2026)
Coherus Oncology (CHRS) Return on Capital Employed Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | - |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 473.74 Bn | 468.95 Bn | 1.35 Bn | 4,893.00 |
| 5 | Vertex Pharmaceuticals | 122.07 Bn | 114.82 Bn | 2.59 Bn | -494.00 |
| 6 | Regeneron Pharmaceuticals | 70.00 Bn | 61.24 Bn | 3.31 Bn | -649.00 |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 4,853.00 |
| 10 | Coherus Oncology | 199.82 Mn | 32.78 Mn | 8.50 Mn | -5,576.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5,576.00 |
| Dec 31, 2025 | -522.00 |
| Sep 30, 2025 | -10,596.00 |
| Jun 30, 2025 | -8,333.00 |
| Mar 31, 2025 | -7,780.00 |
| Dec 31, 2024 | -5,463.00 |
| Sep 30, 2024 | -2,635.00 |
| Jun 30, 2024 | -4,839.00 |
| Mar 31, 2024 | -11,823.00 |
| Dec 31, 2023 | -9,700.00 |
| Sep 30, 2023 | -9,332.00 |
| Jun 30, 2023 | -13,001.00 |
| Mar 31, 2023 | -12,842.00 |
| Dec 31, 2022 | -11,067.00 |
| Sep 30, 2022 | -6,606.00 |
| Jun 30, 2022 | 2,410.00 |
| Mar 31, 2022 | 13,978.00 |
| Dec 31, 2021 | 18,602.00 |
| Sep 30, 2021 | 8,618.00 |
| Jun 30, 2021 | 10,660.00 |